Tags

Type your tag names separated by a space and hit enter

Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
World J Biol Psychiatry. 2009; 10(4 Pt 2):416-9.WJ

Abstract

Aripiprazole, a partial dopamine agonist has been reported to help reduce symptoms of tardive dyskinesia (TD). In a prospective, open label study of a series of cases, we examined the effectiveness of aripiprazole in reducing TD symptoms. Six clinically stable patients with schizophrenia or Schizoaffective disorder and a moderate to severe TD participated in this study. They were systematically cross-titrated from their current medication to aripiprazole and maintained for 16 weeks. The mean extra pyramidal symptom score measured by Abnormal Involuntary Movement Scale (AIMS) improved from a baseline score of 15.8 to final score of 5 (paired t-test; P=0.0009). The severity of psychiatric symptoms remained unchanged. This study supports our hypothesis that clinically stable patients with moderate tardive dyskinesia who are under treatment with other first- or second-generation antipsychotics may benefit from switching to aripiprazole with a reduction of TD symptoms but with out any significant benefit in psychiatric symptoms. The results need to be viewed with caution and not considered as indicative of a viable treatment option for TD as this is an open label study, and a small sample size.

Authors+Show Affiliations

Wayne State University School of Medicine, Detroit, MI, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19492247

Citation

Rajarethinam, Rajaprabhakaran, et al. "Use of Aripiprazole in Tardive Dyskinesia: an Open Label Study of Six Cases." The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, vol. 10, no. 4 Pt 2, 2009, pp. 416-9.
Rajarethinam R, Dziuba J, Manji S, et al. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. World J Biol Psychiatry. 2009;10(4 Pt 2):416-9.
Rajarethinam, R., Dziuba, J., Manji, S., Pizzuti, A., Lachover, L., & Keshavan, M. (2009). Use of aripiprazole in tardive dyskinesia: an open label study of six cases. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, 10(4 Pt 2), 416-9. https://doi.org/10.1080/15622970902995612
Rajarethinam R, et al. Use of Aripiprazole in Tardive Dyskinesia: an Open Label Study of Six Cases. World J Biol Psychiatry. 2009;10(4 Pt 2):416-9. PubMed PMID: 19492247.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of aripiprazole in tardive dyskinesia: an open label study of six cases. AU - Rajarethinam,Rajaprabhakaran, AU - Dziuba,John, AU - Manji,Suzanne, AU - Pizzuti,Albert, AU - Lachover,Leonard, AU - Keshavan,Matcheri, PY - 2009/6/4/entrez PY - 2009/6/6/pubmed PY - 2010/3/2/medline SP - 416 EP - 9 JF - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry JO - World J Biol Psychiatry VL - 10 IS - 4 Pt 2 N2 - Aripiprazole, a partial dopamine agonist has been reported to help reduce symptoms of tardive dyskinesia (TD). In a prospective, open label study of a series of cases, we examined the effectiveness of aripiprazole in reducing TD symptoms. Six clinically stable patients with schizophrenia or Schizoaffective disorder and a moderate to severe TD participated in this study. They were systematically cross-titrated from their current medication to aripiprazole and maintained for 16 weeks. The mean extra pyramidal symptom score measured by Abnormal Involuntary Movement Scale (AIMS) improved from a baseline score of 15.8 to final score of 5 (paired t-test; P=0.0009). The severity of psychiatric symptoms remained unchanged. This study supports our hypothesis that clinically stable patients with moderate tardive dyskinesia who are under treatment with other first- or second-generation antipsychotics may benefit from switching to aripiprazole with a reduction of TD symptoms but with out any significant benefit in psychiatric symptoms. The results need to be viewed with caution and not considered as indicative of a viable treatment option for TD as this is an open label study, and a small sample size. SN - 1814-1412 UR - https://www.unboundmedicine.com/medline/citation/19492247/Use_of_aripiprazole_in_tardive_dyskinesia:_an_open_label_study_of_six_cases_ DB - PRIME DP - Unbound Medicine ER -